Health Source-linked briefing

Nogapendekin Alfa Inbakicept Plus BCG Meets Primary End Point, sBLA Planned by Year-End

Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.

Alexandra Gerlach

Original contributor via Pharmacy Times

| November 10, 2026 | 1 min read | Updated Nov 11, 5:00 AM

Nogapendekin Alfa Inbakicept Plus BCG Meets Primary End Point, sBLA Planned by Year-End — Image supplied with the source report: Pharmacy Times.

Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.

Source disclosure

This is a source-linked briefing. Read the original report from Pharmacy Times .

Health Pharmacy Times